All In Biotech

Drug Trial Radar · NCT07633301

A Study of TAK-360 in Adults With Narcolepsy Type 1 (Narcolepsy With Cataplexy)

A Randomized, Double-Blind, Placebo-Controlled Trial to Evaluate the Safety, Tolerability, and Efficacy of TAK-360 for the Treatment of Narcolepsy With Cataplexy (Narcolepsy Type 1)

Last checked: Nov 19, 2026Latest source record: Jun 29, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Recruiting

Status

Recruiting

Enrollment

92

Planned (sponsor's estimate)

Start

Jun 4, 2026

Primary completion

Nov 28, 2027

Study completion Nov 28, 2027

Sponsor

Lead sponsor
TakedaTakeda (TAK)
Sponsor type
Industry
First posted
Jun 8, 2026

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 2
Allocation
Randomized
Model
Parallel
Masking
Triple (participant, investigator, outcomes assessor)
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years, up to 70 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

Narcolepsy is a sleep disorder that disrupts a person's regular sleep-wake cycle. It causes extreme sleepiness during the day (called excessive daytime sleepiness \[EDS\]), where a person may fall asleep without warning. Narcolepsy Type 1 (NT1) is a form of the condition in which people also have sudden, unexpected muscle weakness while staying conscious (called cataplexy). The main aim of this study is to learn how safe TAK-360 is and how well adults with NT1 tolerate it. Adults who can participate in the study will have to stop taking their existing medicines for NT1 before study treatment starts. Participants may be randomly (by chance, like drawing names from a hat) assigned to get either TAK-360 or placebo during the treatment period. The placebo looks just like TAK-360 but does not have any medicine in it. After the treatment period, participants can be monitored for another 2 weeks. Participants can restart their usual NT1 treatment after study treatment ends. The participants will have to visit the clinic multiple times during this study.

Conditions

  • Narcolepsy Type 1

Interventions

  • TAK-360Drug

    TAK-360 tablet

  • PlaceboDrug

    TAK-360 matching placebo tablet

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Parts A, B and C: Number of Participants With at Least One Treatment-emergent Adverse Events (TEAEs)Time frame: Up to approximately 28 weeks

Locations

18 sites in 7 countries. Site status is shown where the registry gives one.

  • Takeda Site 12

    Redwood City, California · Not yet recruiting

  • Takeda Site 14

    Miami, Florida · Recruiting

  • Takeda Site 13

    Cincinnati, Ohio · Recruiting

  • Takeda Site 2

    Macquarie Park, New South Wales, Australia · Not yet recruiting

  • Takeda Site 4

    Beijing, Beijing Municipality, China · Recruiting

  • Takeda Site 3

    Guangzhou, Guangdong, China · Recruiting

  • Takeda Site 5

    Zhengzhou, Henan, China · Recruiting

  • Takeda Site 7

    Paris, France · Not yet recruiting

  • Takeda Site 6

    Herault, Montpelier, France · Not yet recruiting

  • Takeda Site 8

    Bologna, Emilia-Romagna, Italy · Not yet recruiting

  • Takeda Site 9

    Verona, Veneto, Italy · Not yet recruiting

  • Takeda Site 17

    Fukuoka, Fukuoka, Japan · Recruiting

  • Takeda Site 1

    Kumamoto, Kumamoto, Japan · Recruiting

  • Takeda Site 18

    Isahaya-shi, Nagasaki, Japan · Recruiting

  • Takeda Site 15

    Yodogawa-ku, Osaka-shi, Osaka, Japan · Not yet recruiting

  • Takeda Site 16

    Shinjuku-ku, Tokyo, Japan · Recruiting

  • Takeda Site 11

    Barcelona, Spain · Not yet recruiting

  • Takeda Site 10

    Madrid, Spain · Not yet recruiting

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.